deltatrials
Completed PHASE1 INTERVENTIONAL 5-arm NCT02124148

A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer

A Phase 1b Trial of LY2606368 in Combination With Chemotherapy or Targeted Agents in Advanced and/or Metastatic Tumors

Sponsor: Eli Lilly and Company

Conditions Breast Cancer Colorectal Neoplasms Neoplasm Metastasis
Interventions Cetuximab Cisplatin Fluorouracil G-CSF LY3023414 Leucovorin Pemetrexed Prexasertib
Updated 18 times since 2017 Last updated: Mar 30, 2020 Started: Jun 18, 2014 Primary completion: Feb 13, 2020 Completion: Feb 13, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Breast Cancer and Colorectal Neoplasms, this trial is completed. The trial is conducted by Eli Lilly and Company and has accumulated 18 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshot~Apr 2017 – ~Sep 2017 · 5 months · monthly snapshot~Sep 2017 – ~Jun 2018 · 9 months · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Mar 2019 · 59 days · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~May 2020 · 10 months · monthly snapshot~May 2020 – ~Jan 2021 · 8 months · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 23 months · monthly snapshot

Change History

18 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. May 2020 — Jan 2021 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  5. Jul 2019 — May 2020 [monthly]

    Active Not Recruiting PHASE1

▶ Show 13 earlier versions

  1. Jun 2019 — Jul 2019 [monthly]

    Active Not Recruiting PHASE1

  2. May 2019 — Jun 2019 [monthly]

    Active Not Recruiting PHASE1

  3. Apr 2019 — May 2019 [monthly]

    Active Not Recruiting PHASE1

  4. Mar 2019 — Apr 2019 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  5. Jan 2019 — Mar 2019 [monthly]

    Recruiting PHASE1

  6. Dec 2018 — Jan 2019 [monthly]

    Recruiting PHASE1

  7. Nov 2018 — Dec 2018 [monthly]

    Recruiting PHASE1

  8. Oct 2018 — Nov 2018 [monthly]

    Recruiting PHASE1

  9. Jun 2018 — Oct 2018 [monthly]

    Recruiting PHASE1

  10. Sep 2017 — Jun 2018 [monthly]

    Recruiting PHASE1

  11. Apr 2017 — Sep 2017 [monthly]

    Recruiting PHASE1

  12. Feb 2017 — Apr 2017 [monthly]

    Recruiting PHASE1

  13. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1

    First recorded

Jun 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eli Lilly and Company
Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations